Latest Earnings Results: Q3 '26
Estimated EPS
-$0.56
Reported EPS
-$0.46
Surprise
+17.34%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.46 up 67.38% YoY • Cellectar believes its September 30, 2026 cash balance is adequate to fund budgeted operations into the second quarter of 2027; Phase 3 dosing remains on track for Q1 2027, with NDA submission planned in 1H27.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.49 | -- | -- | N/A |
Q3 '26 | -$0.56 | -$0.46 | 17.34% | BEAT |
Q2 '26 | -$0.59 | -$0.57 | 2.98% | BEAT |
Q1 '26 | -$1.88 | -$1.33 | 29.44% | BEAT |
Q4 '25 | -$1.22 | $0.65 | 153.07% | BEAT |